Nasopharyngeal Neoplasms Clinical Trial
Official title:
A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine Encoding Epstein-Barr Virus Target Antigens
This is a phase I, dose escalation trial of MVA-EBNA1/LMP2 vaccine across a pre-defined range of doses in patients in remission having had an EBV+ nasopharyngeal carcinoma (NPC).
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT00577057 -
Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer
|
N/A | |
Recruiting |
NCT02945878 -
Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Carcinoma
|
N/A | |
Terminated |
NCT02874651 -
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
|
Phase 2 | |
Not yet recruiting |
NCT05807880 -
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
Completed |
NCT00342147 -
Family Study of Head and Neck Cancers in Taiwan
|
||
Recruiting |
NCT02980315 -
A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01735409 -
Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT00630149 -
Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy
|
Phase 2 | |
Completed |
NCT00565448 -
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
|
Phase 2 | |
Active, not recruiting |
NCT03854838 -
IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.
|
Phase 2 | |
Completed |
NCT01797900 -
The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT
|
Phase 2 | |
Completed |
NCT00436800 -
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT00563927 -
Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
|
N/A | |
Not yet recruiting |
NCT04870905 -
Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT02902432 -
A Trial of Endostar in Patients With Carcinoma of the Head and Neck
|
Phase 2 | |
Active, not recruiting |
NCT02456506 -
Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.
|
N/A | |
Completed |
NCT02444949 -
A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
Completed |
NCT00188877 -
Intensity Modulated Radiation Therapy for Head and Neck Cancer
|
Phase 2 | |
Terminated |
NCT00393224 -
Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families
|
||
Not yet recruiting |
NCT03093649 -
Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma
|
N/A |